18 results
8-K
EX-99.1
MLYS
Mineralys Therapeutics, Inc.
13 Aug 24
Mineralys Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update
4:07pm
team will host a conference call at 4:30 p.m. ET on Tuesday, August 13, 2024. To access the call, please dial 1-877-407-9127 in the U.S. or 1-201-689
8-K
EX-99.1
MLYS
Mineralys Therapeutics, Inc.
9 May 24
Mineralys Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
7:07am
. ET on Thursday, May 9, 2024. To access the call, please dial 1-888-886-7786 in the U.S. or 1-416-764-8658 outside the U.S., followed by the conference
424B5
MLYS
Mineralys Therapeutics, Inc.
11 Apr 24
Prospectus supplement for primary offering
4:35pm
incorporated by reference in this prospectus or any accompanying prospectus supplement.
You may also access these documents on our website, https … agencies. DTCC is owned by the users of its regulated subsidiaries. Access to the DTC system is also available to others, which we sometimes refer
DEF 14A
MLYS
Mineralys Therapeutics, Inc.
9 Apr 24
Definitive proxy
7:15am
a live webcast. We have designed the virtual format for ease of stockholder access and participation. The matters to be considered by stockholders … that allow companies to furnish proxy materials to their stockholders by providing access to these documents on the Internet instead of mailing printed
8-K
EX-99.1
MLYS
Mineralys Therapeutics, Inc.
21 Mar 24
Mineralys Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
7:43am
at 8:30 a.m. ET on Thursday, March 21, 2024. To access the call, please dial 1-888-886-7786 in the U.S. or 1-416-764-8658 outside the U.S., followed
S-3
EX-1.2
y0fo31
21 Mar 24
Shelf registration
7:30am
S-3
itl6z2u02qx4urwy
21 Mar 24
Shelf registration
7:30am
8-K
EX-10.1
6lu9f2 zr5ykxch3hfli
8 Feb 24
Mineralys Therapeutics Announces $120 Million Private Placement Financing
4:41pm
8-K
EX-99.1
6m5sy48e65ebo7g3cx0
7 Nov 23
Mineralys Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update
4:07pm
8-K
EX-99.1
b0neinc0tj9tnqoci
7 Aug 23
Mineralys Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update
4:08pm
8-K
EX-99.1
ftmu7wjdokgm9uqvf
15 May 23
Mineralys Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update
4:04pm
DRS/A
nxsolt7llr38xo
29 Dec 22
Draft registration statement (amended)
12:00am
DRS/A
olz9x l4ddt46
7 Dec 22
Draft registration statement (amended)
12:00am
DRS
px3 d5gio0eqf89c
4 Nov 22
Draft registration statement
12:00am
DRS
EX-4.2
n4mebp10
4 Nov 22
Draft registration statement
12:00am
DRS
EX-10.9
i2f 1mdlql75v8dn3
4 Nov 22
Draft registration statement
12:00am
DRS
EX-10.1
5khd1
4 Nov 22
Draft registration statement
12:00am
- Prev
- 1
- Next